Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment

NCT02550106 · clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
136
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Novartis Pharmaceuticals